Pure Hospitality Solutions announced that it is partnering with Investors Hangout to provide additional investor information to shareholders about the Company. Interested parties can visit the Investor board to engage in virtual conversation about Pure Hospitality solutions at http://investorshangout.com/Pure-Hospitality-Solutions-Inc-PNOW-65267.

Melvin Pereira, President and CEO of Pure Hospitality Solutions, Inc. commented, “With all of the ‘pump-and-dump’ and ‘bashing’ boards that exist out there, we are very pleased to partner with a platform that is in the midst of changing how these boards operate. Investors Hangout does not allow frivolous comments one way or the other; no excessive praising or bashing, just facts communicated by our Company or inquiries from shareholders/investors seeking additional information. From a programming perspective, this platform is top-notch… One can see that there is a true webmaster running the Company, not someone looking to extort money or information as other major platforms attempt to do.”

PNOW management has noted that their association with Investors Hangout is designed to offer an added alternative information source for current and perspective shareholders. “With all the progress we’re experiencing behind the scenes, we’re happy to have another distribution channel in which to post our information,” Pereira continued. “Not only will we have new eyes viewing our information, we now have a platform that we can upload our information to, aside from our website, which should continue to help steadily grow our investor base.”

Pure Hospitality Solutions views the Investors Hangout partnership as an effective way to present factual information. In summary, Pereira said, “There’s very little that annoys me more than people posting fake, misleading and deceptive information around the internet. We all know of the ‘hubs’ out there that have members constantly posting frivolous information in an attempt to bring down our value. We urge all our shareholders to break away from the typical hub and visit our Pure Hospitality Solutions page on Investors Hangout to ensure the information you’re reading is legitimate.”

PURE provides proprietary technology, marketing solutions and branding services to hotel operators and condominium owners. PURE looks to build operations in online marketing and hotel internet booking engine services, hotel branding and own, operate and occasionally develop, boutique hotels under the new, “by PURE” brand.

For more information on the company visit www.purenow.solutions

Let us hear your thoughts: Oriens Travel and Hotel Management Corp. Message Board

hopTo is providing a new standard in mobile productivity through the continued development of its hopTo workspace platform. The company’s proprietary system enables users to search, access, create, edit and share content directly from their mobile devices without compromising enterprise security by saving documents directly to a cloud drive or corporate network. Through its dedication to allowing production without boundaries, hopTo has established a presence on the leading edge of mobile development.

Mobile solutions for enterprise productivity have seen an explosion in overall popularity over recent years. According to digital advertising agency Vertic, an estimated 96.3 million enterprise tablets are expected to be shipped by 2016. When accounting for the presence of ‘bring your own device’ (BYOD) options at many companies, it’s clear to see that the market for mobile productivity solutions is both substantial and rapidly expanding.

Despite the natural evolution of companies toward mobile infrastructure, two major concerns have limited the market’s growth in previous years: cost and security. The hopTo Work mobile app addresses both of these concerns, giving hopTo a strong strategic edge as the market continues to mature.

To address cost concerns, the company’s platform leverages existing infrastructure. By allowing users to avoid the need for additional hardware or software, hopTo eliminates complicated installation processes and costly startup expenditures. In this way, the company gives its customers the means to increase employee productivity without burdening existing IT personnel. Additionally, the ability to control accessibility remotely ensures that corporate data is always secure. This allows organizations to utilize a BYOD approach to mobility without risking sensitive data in the event of a lost device or termination of employment.

In the first quarter of 2015, hopTo has experienced promising growth that should propel the company towards continued prosperity in the competitive industry. With revenue growth of approximately ten percent from the previous year and the formation of powerful strategic partnerships, hopTo is in a strong position moving forward.

“We are pleased with the momentum that is taking place with the demand for hopTo Work,” stated Eldad Eilam, President and Chief Executive Officer of hopTo. “Feedback from our customers, prospective customers and the customers of our channel partners is extremely positive and we are beginning to see acceptance in many large international markets as well as the U.S.”

On the heels of an announced distribution agreement with Adapt Software – a Microsoft Gold Certified Partner with over 1,200 clients, including GE, Samsung and Vodafone – hopTo is continuing to establish a powerful presence in the global mobile productivity market. As the company continues to refine and expand its product offerings, look for hopTo to realize significant growth opportunity in the years to come.

For more information, visit www.hopto.com

OncoSec Medical, Inc. is a biotechnology company pioneering new technologies designed to stimulate the body’s immune system to target and attack cancer. The company is currently conducting preclinical and clinical studies targeting various cancers using its proprietary investigational platform, ImmunoPulse™. Early study results have laid the groundwork for OncoSec’s eventual expansion into new DNA-encoded therapeutic candidates and tumor indications, which will allow the company to continue on its mission to harness the body’s immune system and take the fight against cancer directly to the tumor.

Based in San Diego, OncoSec currently has a promising clinical pipeline with four ongoing studies utilizing both monotherapy with the company’s ImmunoPulse™ IL-12 immunotherapy platform and specialized combination therapy. The company is currently proceeding with trials studying the safety and efficacy of its platform in treating multiple stages of metastatic melanoma, head and neck cancer, and triple negative breast cancer. These studies could prove to be monumental in the global battle against various forms of cancers, as illustrated by statistical data surrounding melanoma.

Despite accounting for less than two percent of skin cancer cases, melanoma causes a large majority of skin cancer deaths, according to the American Cancer Society. With diagnosis rates steadily increasing for more than three decades, the demand for improved treatment options is at an all-time high. In 2015, it’s estimated that over 73,000 new melanoma cases will be diagnosed and nearly 10,000 people are expected to die from the disease.

ImmunoPulse™ focuses on the delivery of DNA-based interleukin-12 (IL-12), which is a naturally occurring protein that’s been shown as effective in delivering immune-stimulating functions, directly to the tumor through a sequence of short electrical pulses. By establishing a localized presence of this powerful protein in the tumor microenvironment, the patient’s immune system learns to target and attack tumors throughout the body.

Early data from OncoSec’s trials is promising. The company’s multi-center Phase II trial recorded an overall response in nearly one-third of patients, with half of all patients showing complete regression in at least one untreated lesion. By reliably promoting regression in an untreated area, the company has a powerful proof of concept of the effectiveness of its immune system boosting platform.

Promising results have led to several significant collaborations throughout the biopharmaceutical industry for OncoSec. To date, the company is working with Merck, Heat Biologics, PerkinElmer and Plexxikon on clinical and preclinical collaborations to further study the effectiveness of its ImmunoPulse™ platform.

“With the support of our shareholders, we look forward to validating our ImmunoPulse™ technology in clinical and preclinical studies, generating more value for our investors, and securing our place in this long-awaited revolution in cancer treatment,” stated Punit Dhillon, Chief Executive Officer and President of OncoSec.

For more information, visit www.oncosec.com

An aging population is currently highlighting the considerable limitations of the medical industry. According to the Mayo Clinic, treatments are increasingly unable to keep pace with the needs of patients, with clinicians only having access to medications or devices that can manage symptoms. However, advances in developmental and cell biology, immunology and related fields have unlocked huge potential for the industry, and regenerative medicine looks to be the game-changing solution.

Despite its promise, regenerative medicine faces significant hurdles moving forward. In particular, immune rejection of transplanted cells has severely limited the huge potential of stem cell therapy. International Stem Cell Corporation (OTCQB: ISCO), through its powerful new stem cell technology, could be on the cusp of overcoming these limitations, opening the door for major advances in the medical market.

Parthenogenesis, ISCO’s proprietary stem cell development process, has allowed the company to develop a new class of stem cells, known as human parthenogenetic stem cells (hpSCs), which possess the most favorable characteristics of the existing classes. Through this technique, ISCO is able to create cells that are exactly matched or histocompatible with large segments of the human population, limiting the risk of immune rejection during treatment.

ISCO has made noteworthy strides towards the commercialization of its cell therapy treatment this year, capturing the attention of industry experts around the globe.

“In the first quarter of 2015 we completed all the necessary preclinical studies of our Parkinson’s program and formally submitted our application to begin the first clinical study of this novel approach to treating this debilitating disease in humans,” stated Andrey Semechkin, Ph.D., Chief Executive Officer and Co-Chairman of ISCO.

Highlights from the company’s business activity thus far in 2015 include the completion of preclinical studies and submission of an application to begin human trials in Australia, completion of manufacture of a bank of 2.6 billion human cells for use in clinical trials and the approval of a Japanese patent covering parthenogenetic methods of stem cell creation, meaning ISCO now has patent protection in all three major world markets (US, EU and Japan).

“We continue to expect to make significant progress during the rest of 2015 towards our goal of providing a viable treatment option for people with Parkinson’s disease,” continued Semechkin.

According to Florida Hospital, Parkinson’s disease affects up to one million people in the United States, with doctors diagnosing as many as 60,000 new cases each year. Upon completion of clinical trials, the potential market for ISCO’s parthenogenetic cell creation is effectively limitless. As the company continues towards marketization for the treatment of Parkinson’s disease, look for substantial opportunities for growth within the medical industry in the years to come.

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Car Monkeys Group (OTC: CKMY) is actively transforming the landscape of the used auto parts market with a highly sophisticated search engine that can intelligently locate compatible parts for a given vehicle make/model and year, and which is able to even correlate compatibility across multiple brands, allowing users to shop from the convenience of their home or the office, and still find an exact fit part for their needs. The lack of truly advanced technology in this area has made the process of finding used parts time consuming and often unrewarding. On the one hand, the search often results in parts that are either incompatible or of substandard quality. On the other hand, the search is inordinately costly, as the consumer leaves the job up to their mechanic to find the part, resulting in an even bigger repair bill, due primarily to the high labor cost of most mechanics, which can often run as high as $100 an hour.

The market for used auto parts is hotter than ever today, with used car sales on the rise, as budget-minded Americans look to squeeze ever tighter returns out of their automotive dollar. And used auto parts are also increasingly thought of as green parts by many consumers, considering the environmental benefits from part reuse, like offsetting the raw material consumption required to produce new ones. The addition of lower gas prices to this equation has taken an already revved up used car market and sent sales into overdrive. With used cars stealing more and more market share from newer hybrid and electric vehicles among environmentally conscious consumers, as such buyers weigh the economical and environmental benefits with great care, ultimately seeing the compelling value arguments inherent in buying a used vehicle.

Even as new car sales rose last year to the highest levels since 2006, sales margins continued to decline from 2013 figures, which even then saw a 7 percent fall from the year prior. Average pretax profit for car dealerships was in the neighborhood of 2.2 percent on new vehicle sales according to the National Automobile Dealers Association (NADA), making the used car market a big and growing target for dealerships across the country. During the same period, used car sales margins increased handsomely, up 13 percent. Little wonder then that used car sales hit 42 million last year and are expected to outpace estimates for 2015, as improved credit availability and a generally positive consumer confidence outlook combine to improve throughput. The generally positive consumer confidence that has led to multiple consecutive years of rising auto sales in the U.S. is exemplified by this week’s report from research group The Conference Board, which showed a slight uptick to 95.4 on their consumer confidence index for May.

Used car sales are currently hovering around 9 million per quarter, with franchise certified pre-owned sales seeing the biggest year-over-year increase, up around 13 percent from Q3 2013 to Q3 2014. For full year 2014, used car sales between private parties were also up, by around 4 percent, to roughly 12.5 million according to Edmunds.com’s used market quarterly report, further indicating to investors how strong the used car market is. Infiniti Research even projects a 6.95 percent CAGR moving forward for the 2014 to 2019 period and the underlying message is thus quite clear when it comes to the approximately $3 billion domestic market for used auto parts needed to keep all these used cars going. It is a great time to be innovating in the used auto parts market and Car Monkeys Group is one of the more interesting players to take a look at.

While dealers are struggling to court this booming used car market, which is highly attractive from a widening profit margin and extended services standpoint, using sophisticated digital technologies to engage end-users, the used parts market hasn’t seen the same kinds of innovations we routinely see in other retailer sectors, not until more recently at any rate. The fact that innovators in this space will benefit a great deal from increasing service activity by dealerships, who will need to get their hands on a steady supply of quality used parts, is worth looking into for investors. The advent of companies like Car Monkeys Group, which leverages their proprietary search and consolidation algorithm technology, as well as a growing network of dismantlers across the country, in order to supply users with high quality, run and tested used parts via their easy to use CarMonkeys.com website, is changing the used auto part market and opening up a significant opportunity for investors looking to benefit from the prevailing used car market dynamics.

Once a difficult and time consuming task that often ended up being translated into several additional and costly man hours, the task of locating and laying hands on the right part for a used vehicle has now been transformed into a shopping experience much like Amazon.com or other ecommerce experiences. CarMonkeys.com offers the ease of use that modern consumers have come to expect and harnesses the logistical might of their supplier network to deliver axles, engines, transmissions and other parts, direct to the consumer’s or their mechanic’s doorstep, and all at no shipping cost. The incomparable 5-year unlimited miles warranty and zero hassle 30-day return policy extended by the company have made the barrier for entry to new customers extremely low, allowing CarMonkeys.com to gain immense traction in what is still a relatively niche industry.

The company’s ability to offer top quality used parts via technology that cannot be found elsewhere and which maximally accounts for factors like part interchangeability, delivering the widest possible selection for a low price, further sweetened by exceptional purchasing benefits, has resulted in a great deal of interest and rapidly accruing presence for the Car Monkeys brand, among both individual consumers and car mechanics alike. Moreover, the company’s ability to data mine the vast amount of information generated in the process of site usage gives Car Monkeys key, long-term advantages that can be exploited for increased revenues. Important to note given the company’s recent financial performance reportage, indicating 17.3 percent YOY revenue growth for the six months ending December, 2014, achieved on strong overall volume, with 58 percent YOY growth in the number of gross transactions.

The upper limit on the company’s basic ecommerce used auto parts business model is considerable, especially when one understands the outlook for the used car market, but when you account for the potential upside from their ability to mine the associated big data generated by their revolutionary ecommerce site, the overall value proposition for CKMY increases significantly. Big data is fast emerging as the cornerstone of success in ecommerce for many of the industry’s biggest players and offers several important benefits. From being able to offer improved customer satisfaction the way Amazon does via their big data program, delivering detailed product support and enticing deals to customers based on knowledge that is custom tailored by their own shopping habits (like what kind of car they are buying parts for), to improved new customer engagement and retention, as well as brand awareness metrics, big data is an essential and driving force behind the growth and prosperity of modern ecommerce companies.

CarMonkeys.com has quickly become one of the largest and fastest growing online retailers for used automotive parts here in the U.S. and the sky is the limit given their access to a burgeoning network of dismantling centers, as well as warehousing capacity across the country.

Take a closer look by visiting www.carmonkeys.com

Let us hear your thoughts: Car Monkeys Group Message Board

New investor eyes. That’s what every publicly traded company needs. News releases, social media and articles are a great away to attract investor attention, but a company with substance still places a great value on face-to-face meetings with brokers, investment bankers and most importantly existing and potential shareholders.

Los Angeles-based MIT Holding is a provider of a professional one-source total recovery system that takes a patient from the hospital bed through full recovery. The company takes the responsibility of medications, appointments, the endless calls to the insurance carriers, home visits and, most importantly, the burden and stress of being sick and depending on family and loved ones.

MIT Holdings is gearing up for multiple investor luncheons scheduled for this summer. The luncheons will last approximately two hours and offer attendees one-on-one interaction to hear the full MIT Holding story and receive answers to any lingering questions.

“Even though just about every person alive can relate to our services and business model, because we are the first to create or pioneer this niche in the industry, it takes a little extra personal time to make sure the investor realizes what we have in fact created,” says William Nalley, IR consultant for MIT Holding. “We have reorganized the company and given our shareholders, for the first time, a self-sustaining business that needs no outside funding for day-to-day growth and an organic 25% year-over-year growth.”

Further explaining the business model, Nalley explains, “Think about it; anyone who has ever been through or has had a loved one go through a critical illness and attempt to navigate through the recovery period by themselves would give an arm and a leg to have one company to go to and say, ‘Here is my illness; this is what I need; take care of it!’ Well, we go one step further and meet with you in the hospital prior to discharge and start taking care of it at that moment. We go home from the hospital with you, so all you need to focus on is recovery.”

In support of its core services, MIT Holding also provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Your doctors, your medications and your hospitals will change throughout your life; MIT Holding will not. The company stays with its patients through the rest of their life, taking care of any medical needs that arise.

Combined, these services contribute to MIT Holding’s strategy to provide custom prescription solutions, maximize cross marketing, and generate multiple revenue streams.

MIT Holding has priced its services to achieve 32% minimum net profits and has maintained operational profitability in its fiscal third and fourth quarters, validating the company’s business model, its adaptable approach to the Affordable Health Care Act, and its potential in the health services industry.

Because MIT Holding meets and/or exceeds major U.S. health insurance requirements, the company can direct bill and receive payments from more than 128 carriers, Medicare and Medicaid on behalf of the patient its agents and its facilitators. This is an important component in the company’s goal of developing the first-of its-kind seamless transition for patient needs from hospital discharge to complete home recovery.

The ultimate desired outcome for meeting with brokers and shareholders is to raise brand awareness and transparency, and thereby potentially increase volume and liquidity.

“Once we increase those two factors, we become a different story. These luncheons are just another way to explain our business model and gain momentum,” explains Nalley. “Our intention is to do a year-long, nationwide investment/broker campaign. We’re going in and shaking the hands of brokers and making MIT Holdings management available for questions now and down the road.”

For more information, visit www.mitholdinginc.com

Let us hear your thoughts: MIT Holding, Inc. Message Board

Established in 1998, View Systems, Inc. serves one of the fastest-growing sectors of the global economy: the security industry. The company manufactures computer software and hardware used for threat detection and surveillance applications, giving it access to an estimated $100 billion per year industry. According to an analysis of global threats to government and businesses, this puts View Systems in a strong strategic position to maintain its presence in the global market for the foreseeable future.

The company’s primary product offering, ViewScan, is a proven improvement on traditional Concealed Weapons Detection Systems (CWD). Using a PC-based software display, the system identifies the location and number of threat items, such as knives, guns and razor blades, while ignoring innocuous personal artifacts like coins, keys and belt buckles. By avoiding electro-magnetic fields, radiation, millimeter waves or x-rays, ViewScan provides completely passive security scanning that’s safe for use with pacemakers, implants and during pregnancy.

ViewScan is an ideal solution for venues requiring efficient, high-volume screening because it doesn’t require the removal of jewelry, shoes or personal effects. In addition, the system’s visual interface, which displays the exact location of potentially harmful objects, makes secondary screening quick and easy for security personnel. According to the company’s research, the ViewScan system can scan up to 1,200 persons per hour, representing a significant improvement over traditional electromagnetic induction scanners.

The ViewScan system is currently in use in a variety of vital market segments – including correctional facilities, judicial facilities, probation offices and federal facilities – in states around the country. Using a combination of exclusive technology licensing agreements and continued development and refinement of its product lines, View Systems has established itself as a major player in the expanding security industry. In April, the company continued on this trend by filing for a patent on its newly enhanced ViewScan platform.

The company’s product line appears to place View Systems in a strong position for continued growth moving forward. With a recorded 5.7 percent of public schools implementing CWDs for enhanced security during the 2011 school year, according to the Institute of Education Sciences, it’s clear that View Systems will have ample opportunity for further expansion into a variety of vital market segments. Look for further refinement of its product line and penetration of new industry sectors to set the stage for substantial opportunity for this promising company in the years to come.

For more information, visit www.viewsystems.com

Let us hear your thoughts: View Systems, Inc. Message Board

CannabisFN this morning highlighted GROWBlox Sciences’ role in the cannabis and pharmaceutical industries, paying particular attention to the company’s “unique business model, long-term potential in pharmaceuticals, and short-term potential in raw material sales.”

Read the full report here: http://www.marketwatch.com/story/growblox-sciences-takes-integrated-approach-to-cannabis-medicine-2015-05-25?page=1

Twenty three U.S. states and the District of Columbia have legalized marijuana, and according to IBISWorld estimates, broader acceptance of cannabinoid-based therapies throughout the U.S. has spurred the medical cannabis industry’s CAGR of 16.2% to reach $2 billion in revenue between 2009 and 2014.

As CannabisFN points out, GROWBlox Sciences stands out from numerous would-be competitors in the industry with its cutting-edge plant biology and cultivation technologies and scientific team comprised of professionals in multiple areas of relevant medicine:

• Chief Science Officer Dr. Andrea Small-Howard
• Big data expert Dr. Long Nguyen
• Botanical expert Dr. Ulrich Reimann-Philipp
• Immunologist expert Dr. Helen Turner
• Small molecule expert Dr. Tony Ortiz
• Clinical investigator expert Dr. Daniel Chueh
• Orthopedic expert Dr. Alfredo L. Axtmayer
• Liver disease expert Dr. John Abroon

Whereas many companies in the cannabis industry administer generic forms of THC or CBD in an attempt to elicit a desired response, says CannabisFN, GROWBlox’s approach is to correlate the profiles of active ingredients within cannabis, including cannabinoids and terpenes, with the symptom and disease-specific improvements in patient outcomes – putting the company at high valuation potential when it comes to market application and opportunity.

The report notes:

“Based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, the company has identified the most effective cannabinoid and terpene profiles for the treatment of conditions within seven therapeutic categories, including cancer treatments, cardio protection, metabolic syndrome, pain management, neurological disorders, and inflammation.

“These categories represent hundreds of billions of dollars in potential value, with markets like the neurological disorder market alone accounting for $952 billion in value. By taking a targeted approach that leverages research already done, the company’s strategy could dramatically improve the odds of success, whilst cutting down on the costs associated with hit-or-miss early stage testing.”

CannabisFN also highlights several other differentiating advantages, including an accelerated drug development and regulatory strategy.

GROWBlox’s proprietary drug discovery program enables drug development within three to five years instead of the traditional 15 to 20 years. This strategy also significantly reduces development costs – which typically sit around $1 billion for “big pharma” pharmaceutical commercialization – to less than $10 million.

Using its proprietary smartphone app as a drug discovery engine, GROWBlox correlates strain profile information with symptom relief and then leverages the existing cannabis safety profiles, fast-track approvals, and orphan drug designations, of research partners, which are incentivized with equity in proportion to the value of data contributed that becomes part of a patent, IND filing, or NDA filing with regulatory bodies.

“In essence, the company is focused on the initial discovery of promising compounds, while universities handle pre-clinical trials, CROs handle clinical trials, and pharmaceutical partners handle distribution. The discovery phase provides the greatest return on capital and diversification relative to other areas of the development process that are much more capital intensive,” the report states.

CannabisFN wraps up the report by highlighting GROWBlox’s end-to-end operations and technologies, the company’s long-term and short-term potential, and broader peer comparison.

“GROWBlox Sciences has clear long-term potential with its innovative approach that leverages big data to produce lower-risk clinical trial candidates. With 188 human cannabis trials registered with the National Institute of Health and more on the way, the company has an excellent starting point of about a thousand potential combinations within the cannabinoid-related therapy space.

“In the nearer-term, the company plans on earning revenue from the sale of certified raw materials through dispensaries. These plans were solidified in May when it announced the formation of Growblox Sciences Puerto Rico LLC, which will legally grow cannabis raw materials that will be exclusively sold to GROWBlox Sciences for distribution in the U.S. and other countries where it’s legal …

“The nutraceutical and cosmeceutical formulations could also be sold in stores without approvals, since the CBDs are sourced from low-THC hemp plants. In some ways, the company could then compete with the likes of GNC Holdings Inc., or Nutraceutical International Corp. in the provision of legal over-the-counter supplements designed to support health.”

For more information, visit www.gbsciences.com

Let us hear your thoughts: Growblox Sciences, Inc. Message Board

CytRx Corp., a biopharmaceutical research and development company specializing in oncology, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer, and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the Jefferies 2015 Global Healthcare Conference on Tuesday, June 2, 2015 at 1:30 p.m. Eastern Time. The conference will take place at the Grand Hyatt in New York, NY.

A live and archived webcast of the presentation will be available on the Company’s website at www.cytrx.com/investors/presentations.

Debit cards are viewed as an easy way to access the funds in a person’s checking and savings account. The problem that subsequently surfaces, however, is that should the card or PIN be stolen, overdraft issues become irrevocable. Many of these problems can be prevented by keeping careful track of one’s debit card and the amount of money that is currently in the account. Easier said than done.

Despite vigilant habits around keeping track of one’s card, numbers can still be stolen after or while the card is being used at a merchant site or via online shopping environments. Generally speaking, it is a good idea to use a credit card versus a debit card online because it is a simpler process to get fraudulent purchases removed from a credit card than to replace money that was stolen from a checking account.

Additionally, it is always wise to not let anyone see the PIN associated with the debit card as this can lead to problems with a debit card as well. If someone does learn the PIN, the consumer must contact the bank to find out if it can be changed. Further stop gaps to falling victim to fraud involve reviewing the bank statement every month, and report any fraudulent charges as soon as possible.

A San Diego, California company has taken the subject of debit card fraud into their own hands by aiming to eliminate it altogether. IFAN Financial (OTC: IFAN) builds shareholder value by developing and testing technology that connects to your mobile device or computer, which enables the consumer to transfer funds without having to reveal their associated account numbers.

IFAN centers its time and resources on exploring market opportunities to build its product portfolio to meet the growing demands for consumer/merchant security, convenience and expediency within the mobile commerce market. The company’s products in development are expected to integrate social media dynamics, banking and e-commerce with the pervasiveness of today’s mobile culture.

For more information on the company, visit http://ifanfinancial.com

Let us hear your thoughts: IFAN Financial, Inc. Message Board